Gene therapy

DNA vector
#AAV #Duchenne muscular dystrophy #Gene therapy #Hansa Biopharma

Data supports imlifidase prior to gene therapy for Duchenne

Hansa Biopharma has announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with its imlifidase prior to receiving Sarepta’s Elevidys (delandistrogene moxeparvovec-rokl) in the SRP-9001-104 trial.  After one dose of imlifidase, three patients experienced a rapid reduction of IgG antibodies, to levels ≥95% less… Read More

#News

Cell and gene therapy
#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Manufacturing #MHRA #UK

Landmark UK legislation improves access to personalised therapies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.  The new legislation ‘The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations… Read More

#News #Trending News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy

New DDW Highlights podcast: 21 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s news highlights reflect the incredible levels of innovation and investment, but also the… Read More

#News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy

This week in drug discovery (14-18 July) 

News round-up for 14-18 July by DDW Senior Digital Content Editor Diana Turner. This week’s news highlights reflect the incredible levels of innovation and investment, but also the hurdles to overcome, in developing gene therapies – breakthrough treatments in many genetic diseases that can bring their own unique… Read More

#News

#Duchenne muscular dystrophy #Gene therapy #Restructuring #Sarepta Therapeutics

Sarepta Therapeutics focuses pipeline and cuts 36% of workforce

Sarepta Therapeutics has announced a strategic restructuring plan designed to prioritise high-value, high impact programmes, and support its long-term financial viability.   This plan includes a 36% workforce reduction, impacting approximately 500 employees, and an emphasis on near- and mid-term opportunities from the siRNA platform.  Several… Read More

#Business & Investment #News

FDA
#AAV #FDA #Gene therapy #Manufacturing #Rare disease #Ultragenyx

FDA raises manufacturing concerns for Ultragenyx gene therapy

The US Food and Drug Administration (FDA) has decided not to recommend Ultragenyx Pharmaceutical’s UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA).   In its complete response letter (CRL), the FDA requested that the company provide additional information and… Read More

#News #Regulatory #Trending News

#Alzheimer's #Gene therapy #Neuroscience #Voyager Therapeutics

Voyager adds fourth Alzheimer’s disease programme to pipeline

Voyager Therapeutics has added a new programme that modulates the expression of apolipoprotein E (APOE), the strongest genetic risk factor for Alzheimer’s disease (AD).  The programme uses a proprietary intravenous (IV)-delivered, blood-brain barrier (BBB)-penetrant TRACER capsid to deliver a bifunctional payload that is designed to decrease expression… Read More

#News

Adenovirus
#AAV #Alexion #Drug delivery #Gene therapy #JCR Pharmaceuticals #License agreement

JCR and Alexion deal boosts AAV-based gene therapy

JCR Pharmaceuticals and Alexion, AstraZeneca Rare Disease, have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicines.  JUST-AAV encompasses a range of vector types optimised for various target tissues—including liver-sparing, muscle-targeting, and brain-targeting variants—to expand the potential of AAV-based gene therapy. … Read More

#Business & Investment #News

#Atsena Therapeutics #Clinical trial #FDA #Gene therapy #Ophthalmology

Atsena expedites gene therapy for X-linked retinoschisis

The US Food and Drug Administration (FDA) has agreed to the expansion of Atsena Therapeutics’ ongoing Phase I/II LIGHTHOUSE study of ATSN-201 into a continuous Phase I/II/III trial in the treatment of X-linked retinoschisis (XLRS).   “This regulatory milestone marks another significant step toward delivering a potentially first-… Read More

#News #Regulatory

Blood cells
#CSL Behring #Early access #Gene therapy #Haematology #Haemophilia

First patient receives gene therapy for haemophilia B in Germany

CSL Behring Germany has announced that the first haemophilia B patient in Germany was treated with the gene therapy Hemgenix (etranacogene dezaparvovec) at the Hemophilia Treatment Center at Hannover Medical School. Hemgenix is the first one-time gene therapy approved in Europe for the treatment of adults with severe… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

New DDW Highlights podcast: 7 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In significant news this week, the FDA in the US has removed red tape that… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

This week in drug discovery (30 June – 4 July) 

News round-up for 30 June – 4 July by DDW Senior Digital Content Editor Diana Turner. In significant news this week, the FDA in the US has removed red tape that limits which centres could give CAR-T therapy, in a move to improve access to the therapies. The… Read More

#News

Gene editing
#Eli Lilly #Gene editing #Gene therapy #Mergers and acquisitions #Verve Therapeutics

Lilly to acquire gene editing specialists Verve Therapeutics

Eli Lilly and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve.  Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. … Read More

#Business & Investment #News

#Gene mutation #Gene therapy #Genetic diseases #Genetics / genomics

New DDW Highlights podcast: 16 June 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s round-up highlights the vital role of genetics in drug discovery, including new data… Read More

#News

#Gene mutation #Gene therapy #Genetic diseases #Genetics / genomics

This week in drug discovery (9-13 June) 

News round-up for 9-13 June by DDW Senior Digital Content Editor Diana Spencer. This week’s round-up highlights the vital role of genetics in drug discovery, including new data for an Alzheimer’s gene therapy, the discovery of a genetic target for rejuvenation therapies, and a 13-year follow up on… Read More

#News

Cell and gene therapy
#AAV #Financing #Gene therapy #Genetic diseases #Ophthalmology #SpliceBio

SpliceBio secures $135m to advance gene therapy candidates

SpliceBio has closed a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures.  There was also participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys… Read More

#Business & Investment #News